ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Barcelona, CT

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Cognitive Dysfunction
Alzheimer Disease

Multiple Sclerosis (MS) trials near Barcelona, CT, ESP:

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Active, not recruiting
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Barcelona, Spain and 36 other locations

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Enrolling
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Barcelona, Spain and 76 other locations

A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis

(Part 1), a single-ascending subcutaneous (SC) dose (Part 2), and multiple ascending SC doses (Part 3) of RO7121932 in participants with multiple...

Enrolling
Multiple Sclerosis
Drug: RO7121932 IV
Drug: RO7121932 SC

Phase 1

Roche
Roche

Barcelona, Spain and 31 other locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Esplugues de Llobregat, Barcelona, Spain and 65 other locations

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Barcelona, Spain and 105 other locations

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascendi...

Enrolling
Progressive Multiple Sclerosis
Biological: rapcabtagene autoleucel (YTB323)

Phase 1, Phase 2

Novartis
Novartis

Barcelona, Catalonia, Spain and 16 other locations

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity duri...

Enrolling
Relapsing Multiple Sclerosis
Biological: rapcabtagene autoleucel (YTB323)

Phase 1, Phase 2

Novartis
Novartis

Barcelona, Catalonia, Spain and 15 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Teriflunomide
Drug: Remibrutinib

Phase 3

Novartis
Novartis

Barcelona, Spain and 241 other locations

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)

To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib
Drug: Teriflunomide

Phase 3

Novartis
Novartis

Barcelona, Catalonia, Spain and 249 other locations

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

of remibrutinib after switching from ocrelizumab and compared to continuous ocrelizumab treatment, in patients living with relapsing multiple...

Enrolling
Relapsing Multiple Sclerosis
Drug: Remibrutinib oral treatment
Drug: Ocrelizumab

Phase 3

Novartis
Novartis

Barcelona, Catalonia, Spain and 27 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2025 Veeva Systems